Abstract
Introduction: There is increasing interest in evaluating the quality of life of patients with cortisol-producing adrenocortical adenoma (CPA). Our objective was to assess patient-reported health-related quality of life (HRQOL) in patients with CPA compared to non-CPA. Methods: Between January 2012 and September 2015, a total of 24 and 62 patients who had laparoscopic adrenalectomy with CPA and non-CPA, respectively, were included in the study. General HRQOL was evaluated on Short Form 8 (SF-8) questionnaire. The SF-8 questionnaire was administered at preoperative baseline and at 3, 6, 9, 12, 18, and 24 months after adrenalectomy. The impact of changing 2 measures of the summary score on the physical component summary (PCS) and mental component summary (MCS) score of SF-8 was evaluated in prospective and longitudinal studies. Results: The baseline PCS score was significantly lower in the CPA than in the non-CPA group (43.6 vs. 49.0; p = 0.0075). Thereafter, the PCS score was significantly lower in the CPA group at 3, 6, 9, and 12 months postoperatively. The PCS score increased in the CPA group with no significant difference between both groups at 18 months (48.1 vs. 50.2; p = 0.1202) and 24 months (48.0 vs. 50.8; p = 0.3625) postoperatively. However, the baseline MCS score was not significantly different between the CPA and non-CPA group. The MCS score in both groups gradually increased with no significant differences between the groups at any time points after surgery. The PCS score was not significantly improved at all postoperative points than the baseline score in the CPA and non-CPA group. The MCS score was significantly improved than the baseline score from 6 months postoperatively only in the CPA group. Conclusion: Our research suggests that laparoscopic adrenalectomy may contribute to improving the physical and mental function in HRQOL.
References
1.
Badia
X
, Valassi
E
, Roset
M
, Webb
SM
. Disease-specific quality of life evaluation and its determinants in Cushing’s syndrome: what have we learnt?
Pituitary
. 2014 Apr
;17
(2
):187
–95
. 2.
Webb
SM
, Crespo
I
, Santos
A
, Resmini
E
, Aulinas
A
, Valassi
E
. Management of endocrine disease: quality of life tools for the management of pituitary disease
. Eur J Endocrinol
. 2017 Jul
;177
(1
):R13
–26
. 3.
Webb
SM
, Santos
A
, Resmini
E
, Martínez-Momblán
MA
, Martel
L
, Valassi
E
. Quality of life in Cushing’s disease: a long term issue?
Ann Endocrinol
. 2018 Jun
;79
(3
):132
–7
. 4.
Ragnarsson
O
, Johannsson
G
. Cushing’s syndrome: a structured short- and long-term management plan for patients in remission
. Eur J Endocrinol
. 2013 Oct 4
;169
(5
):R139
–52
. 5.
Aulinas
A
, Valassi
E
, Webb
SM
. Prognosis of patients treated for Cushing syndrome
. Endocrinol Nutr
. 2014 Jan
;61
(1
):52
–61
. 6.
Abraham
SB
, Abel
BS
, Rubino
D
, Nansel
T
, Ramsey
S
, Nieman
LK
. A direct comparison of quality of life in obese and Cushing’s syndrome patients
. Eur J Endocrinol
. 2013 Apr 15
;168
(5
):787
–93
. 7.
Milian
M
, Honegger
J
, Teufel
P
, Wolf
A
, Psaras
T
. Tuebingen CD-25 is a sensitive tool to investigate health-related quality of life in Cushing’s disease patients in the course of the disease
. Neuroendocrinology
. 2013
;98
(3
):188
–99
. 8.
Sugimoto
M
, Takegami
M
, Suzukamo
Y
, Fukuhara
S
, Kakehi
Y
. Health-related quality of life in Japanese men with localized prostate cancer: assessment with the SF-8
. Int J Urol
. 2008 Jun
;15
(6
):524
–8
. 9.
Papakokkinou
E
, Johansson
B
, Berglund
P
, Ragnarsson
O
. Mental fatigue and executive dysfunction in patients with Cushing’s syndrome in remission
. Behav Neurol
. 2015
;2015
:173653
. 10.
Badia
X
, Roset
M
, Valassi
E
, Franz
H
, Forsythe
A
, Webb
SM
. Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing’s syndrome (ERCUSYN)
. Qual Life Res
. 2013 Dec
;22
(10
):2941
–50
. 11.
Nelson
LM
, Forsythe
A
, McLeod
L
, Pulgar
S
, Maldonado
M
, Coles
T
, et al. Psychometric evaluation of the Cushing’s quality-of-life questionnaire
. Patient
. 2013
;6
(2
):113
–24
. 12.
Webb
SM
, Ware
JE
, Forsythe
A
, Yang
M
, Badia
X
, Nelson
LM
, et al. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease
. Eur J Endocrinol
. 2014 Jul
;171
(1
):89
–98
. 13.
Gotch
PM
. Cushing’s syndrome from the patient’s perspective
. Endocrinol Metab Clin North Am
. 1994 Sep
;23
(3
):607
–17
. 14.
Wagenmakers
MA
, Netea-Maier
RT
, Prins
JB
, Dekkers
T
, den Heijer
M
, Hermus
AR
. Impaired quality of life in patients in long-term remission of Cushing’s syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism?
Eur J Endocrinol
. 2012 Nov
;167
(5
):687
–95
. 15.
De Bucy
C
, Guignat
L
, Niati
T
, Bertherat
J
, Coste
J
. Health-related quality of life of patients with hypothalamic-pituitary-adrenal axis dysregulations: a cohort study
. Eur J Endocrinol
. 2017 Jul
;177
(1
):1
–8
. 16.
Tiemensma
J
, Kaptein
AA
, Pereira
AM
, Smit
JW
, Romijn
JA
, Biermasz
NR
. Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing’s syndrome
. Eur J Endocrinol
. 2011 Nov
;165
(4
):527
–35
. 17.
Chiodini
I
, Morelli
V
, Masserini
B
, Salcuni
AS
, Eller-Vainicher
C
, Viti
R
, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian Multicenter Study
. J Clin Endocrinol Metab
. 2009 Sep
;94
(9
):3207
–14
. 18.
Chiodini
I
. Clinical review: diagnosis and treatment of subclinical hypercortisolism
. J Clin Endocrinol Metab
. 2011 May
;96
(5
):1223
–36
. 19.
Ragnarsson
O
, Berglund
P
, Eder
DN
, Johannsson
G
. Long-term cognitive impairments and attentional deficits in patients with Cushing’s disease and cortisol-producing adrenal adenoma in remission
. J Clin Endocrinol Metab
. 2012 Sep
;97
(9
):E1640
–8
. 20.
Tiemensma
J
, Biermasz
NR
, Middelkoop
HA
, van der Mast
RC
, Romijn
JA
, Pereira
AM
. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing’s disease
. J Clin Endocrinol Metab
. 2010 Oct
;95
(10
):E129
–41
. 21.
Dorn
LD
, Burgess
ES
, Friedman
TC
, Dubbert
B
, Gold
PW
, Chrousos
GP
. The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism
. J Clin Endocrinol Metab
. 1997 Mar
;82
(3
):912
–9
. 22.
Jeffcoate
WJ
, Silverstone
JT
, Silverstone
JT
, Besser
GM
. Psychiatric manifestations of Cushing’s syndrome: response to lowering of plasma cortisol
. Q J Med
. 1979 Jul
;48
(191
):465
–72
.23.
Chiodini
I
, Morelli
V
, Salcuni
AS
, Eller-Vainicher
AS
, Eller-Vainicher
C
, Torlontano
M
, Coletti
F
, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism
. J Clin Endocrinol Metab
. 2010 Jun
;95
(6
):2736
–45
. 24.
Mantero
F
, Terzolo
M
, Arnaldi
G
, Osella
G
, Masini
AM
, Alì
A
, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology
. J Clin Endocrinol Metab
. 2000 Feb
;85
(2
):637
–44
. 25.
Sippel
RS
, Chen
H
. Subclinical Cushing’s syndrome in adrenal incidentalomas
. Surg Clin North Am
. 2004 Jun
;84
(3
):875
–85
. 26.
Nieman
LK
, Biller
BM
, Findling
JW
, Newell-Price
J
, Savage
MO
, Stewart
PM
, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline
. J Clin Endocrinol Metab
. 2008 May
;93
(5
):1526
–40
. 27.
Erbil
Y
, Ademoğlu
E
, Ozbey
N
, Barbaros
U
, Yanik
BT
, Salmaslioğlu
A
, et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery
. World J Surg
. 2006 Sep
;30
(9
):1665
–71
. 28.
Iacobone
M
, Albiger
N
, Scaroni
C
, Mantero
F
, Fassina
A
, Viel
G
, et al. The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal hyperplasia (AIMAH)
. World J Surg
. 2008 May
;32
(5
):882
–9
. 29.
Netuveli
G
, Wiggins
RD
, Hildon
Z
, Montgomery
SM
, Blane
D
. Quality of life at older ages: evidence from the English longitudinal study of aging (wave 1)
. J Epidemiol Community Health
. 2006 April
;60
(4
):357
–63
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
